Equillium Bio (EQ): Prakiraan wutah bathi kanggo taun ngarep

The projection of Equillium, Inc. (EQ) EPS for the next year on this GURU.Markets chart demonstrates a value of -19.70. Equillium, Inc. (EQ) creates unique immunomodulators, aiming for a monopoly position in its segment. The business focuses on psoriasis and nephrosis therapy via CD6 receptor blocking for rheumatologists. Further progress is based on the results of molecule clinical trials and stable external funding.

This indicator reflects the analysts' consensus forecast for net profit growth rates for the coming year, measuring expected capital efficiency. Investors utilize the 12-month forward EPS growth vector to decouple short-term volatility from the fundamental earnings trend. For Equillium, Inc. (EQ), such price action depends directly on the successful completion of Phase II trials for immunomodulating antibodies.